Should you buy Fisher & Paykel Healthcare Corp Ltd at this share price?

Is Fisher & Paykel Healthcare Corp Ltd (ASX:FPH) the best growth stock on the ASX?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The investment analysts at Deutsche Bank have according to financial news wires reconsidered the investment case for sleep treatment specialist Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) in the light of recent legal battles it has taken on.

New Zealand-based Fisher & Paykel (FPH) is a manufacturer of continuous positive airway pressure (CPAP) sleep devices and masks for patients with sleep disorders in much the same way as its Australian rival ResMed Inc. (CHESS) (ASX: RMD).

In fact the two companies' technologically advanced machines and devices are so similar that they are currently engaged in simultaneously claiming against each in separate actions for patent infringements in U.S. courts. This law fest may be something of a snooze fest to many, but it's likely to be costing both companies a small fortune, while distracting them from the real operating business of growing sales.

Deutsche Bank reportedly has a hold call on the dual-listed scrip of FPH while valuing its NZ scrip at $NZ$11.15. Whereas the average share price target for ResMed's US-listed scrip is US$65 according to The Financial Times news service.

Outlook

FPH is due to announce its full year results on May 22 and its track record of double-digit growth supported by rising margins in large addressable markets means this is a quality stock highly prized by investors.

It's also in rude financial health with net debt of just NZ$43 million, versus a half-year operating profit after tax of NZ$78.2 million, which climbed 26% on the prior corresponding period.

It also boasts a return on equity of 39% with annualised earnings of 27.6 NZ cents per share. This means the NZ scrip sells for around 36x annualised forward earnings, with the ASX-scrip trading on an equivalent FX-adjusted basis.

Fisher & Paykel looks a quality company, but I would prefer a lower share price as it has the kind of earnings multiple ususally reserved for unstoppably hot tech stocks, rather than fast-growing medical device businesses. Accordingly, I would wait for a lower share price before moving into the stock.

Motley Fool contributor Tom Richardson owns shares of ResMed Inc. You can find Tom on Twitter @tommyr345 The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »